Simon Quoted on Global Anti-Bribery Compliance Standard
October 21, 2016
Wall Street Journal
Partner David Simon was quoted in a Wall Street Journal article, “Anti-Bribery Compliance Gets Global Standard,” on October 21, 2016. The article discussed the first-ever global standard for anti-bribery compliance programs, known as ISO 37001 and issued by the International Standards Organization. The standard was designed to help provide companies with guidance and leverage when dealing with business partners in high-risk countries.
Simon noted that the global standard won’t be a big deal for major U.S. companies that already have anti-bribery compliance programs. He was quoted saying, “The changes track current best practices. It’s the same stuff we’ve seen for forever … just in a more systematic way.”
Simon noted that the global standard won’t be a big deal for major U.S. companies that already have anti-bribery compliance programs. He was quoted saying, “The changes track current best practices. It’s the same stuff we’ve seen for forever … just in a more systematic way.”
People
Related News
August 13, 2025
In the News
Leigh Riley on Elevating Partner Development with Foley's PEAK Program – 'We can't stop learning'
Foley & Lardner LLP partner Leigh Riley appeared on the Big Law Life podcast to share how Foley is redefining professional development to meet the needs of the firm's partners and the demands of modern legal practice.
August 8, 2025
In the News
Gregory Husisian and David Simon Uncover the High Stakes of Tariff Evasion
Foley & Lardner LLP partners Gregory Husisian and David Simon are featured for their insights on how the U.S. government is cracking down on tariff evaders in the Newsweek article, "America Is Making Billions From Catching 'Tariff Cheaters.'"
August 7, 2025
In the News
Kyle Faget Weighs in on Trump Pharma Tariffs
Foley & Lardner LLP partner Kyle Faget assessed the Trump administration's implementation of import tariffs on the pharmaceutical industry in the Pharma Life Sciences article, "Trump's pharma import tariffs threaten drug pricing, generics."